Platinum‐containing chemotherapy leads to higher participants requiring chemotherapy delays compared with chemotherapy without platinum (high certainty).
Platinum‐containing chemotherapy probably leads to higher participants requiring dose reduction compared with chemotherapy without platinum (moderate certainty).
The intervention leads to higher congestive heart failure (CHF) (high certainty).
Summary of Findings Table ‐ PBI?APBI probably leads to higher local recurrence‐free survival ‐ total (LR‐FS) compared with WBRT (moderate certainty).
Summary of Findings Table ‐ PBI?APBI probably leads to higher cosmesis, physician/nurse‐reported compared with WBRT (moderate certainty).
Summary of Findings Table ‐ PBI?APBI showed no clear difference in overall survival compared with WBRT (high certainty).
Summary of Findings Table ‐ PBI?APBI probably leads to higher subcutaneous fibrosis (late RT toxicity) compared with WBRT (moderate certainty).
Summary of Findings Table ‐ PBI?APBI showed no clear difference in cause‐specific survival (C‐SS) compared with WBRT (moderate certainty).
Summary of Findings Table ‐ PBI?APBI showed no clear difference in distant metastasis‐free survival (DM‐FS) compared with WBRT (moderate certainty).
Summary of Findings Table ‐ PBI?APBI showed no clear difference in subsequent mastectomy compared with WBRT (high certainty).